Want to see JP:7702 full AI Analyst Report?
7702 Stock Chart & Stats
¥442.00
-¥3.00(-0.69%)
At close: 4:00 PM EST
¥442.00
-¥3.00(-0.69%)
Day’s Range― - ―
52-Week Range¥418.00 - ¥478.00
Previous CloseN/A
Volume24.60K
Average Volume (3M)25.96K
Market Cap
¥11.43B
Enterprise Value¥31.13B
Total Cash (Recent Filing)¥7.72B
Total Debt (Recent Filing)¥28.01B
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.85%
Share Statistics
EPS (TTM)-31.94
Shares Outstanding24,733,465
10 Day Avg. Volume29,090
30 Day Avg. Volume25,963
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.16
P/FCF Ratio-11.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Revenue ModelJMS's core revenue comes from single-use disposables tied to medical procedures, creating predictable repeat demand. This attachment to recurring clinical workflows (dialysis, infusion, transfusion) supports stable topline inflows and resilience versus one-off device sales, aiding 2–6 month revenue visibility and planning.
Moderate Balance Sheet With Sizable EquityThe company carries meaningful equity relative to debt, providing a capital buffer to absorb cyclical pressures and support operations. While leverage has risen, the current equity base supports financing flexibility and reduces immediate solvency risk, enabling continued investment in distribution and product support.
Operating Cash Flow Remains PositiveConsistent positive operating cash flow indicates the core business converts sales into cash, funding working capital and recurring supply chains. This cash generation underpins day-to-day operations and can fund selective capex or inventory support even if free cash flow is volatile, preserving operational continuity over months.
Bears Say
Deteriorating Profitability And Recent Net LossMargins and bottom-line results have weakened materially, culminating in a recent net loss. Declining revenue and thin operating profit reduce retained earnings and limit ability to invest in product development or commercial expansion. Persistent margin pressure can erode competitive reinvestment capacity.
Volatile And Often Negative Free Cash FlowRecurrent negative free cash flow constrains organic deleveraging and increases reliance on financing or balance sheet reserves. This undermines long-term financial flexibility, limits funding for R&D or international expansion, and raises the risk that the company must divert resources to liquidity management rather than growth initiatives.
Rising Leverage Reduces Financial FlexibilityAn increasing debt ratio amid weakening earnings tightens covenant and interest burden risks. Higher leverage lowers capacity to absorb further shocks or fund strategic investments without external capital. If profitability does not recover, elevated debt amplifies long-term financial vulnerability and limits strategic optionality.
JMS Co., Ltd. News
7702 FAQ
What was JMS Co., Ltd.’s price range in the past 12 months?
JMS Co., Ltd. lowest stock price was ¥418.00 and its highest was ¥478.00 in the past 12 months.
What is JMS Co., Ltd.’s market cap?
JMS Co., Ltd.’s market cap is ¥11.43B.
When is JMS Co., Ltd.’s upcoming earnings report date?
JMS Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 19 days.
How were JMS Co., Ltd.’s earnings last quarter?
JMS Co., Ltd. released its earnings results on May 12, 2026. The company reported -¥27.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥27.71.
Is JMS Co., Ltd. overvalued?
According to Wall Street analysts JMS Co., Ltd.’s price is currently Overvalued.
Does JMS Co., Ltd. pay dividends?
JMS Co., Ltd. pays a Semiannually dividend of ¥8.5 which represents an annual dividend yield of 3.85%. See more information on JMS Co., Ltd. dividends here
What is JMS Co., Ltd.’s EPS estimate?
JMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JMS Co., Ltd. have?
JMS Co., Ltd. has 24,733,465 shares outstanding.
What happened to JMS Co., Ltd.’s price movement after its last earnings report?
JMS Co., Ltd. reported an EPS of -¥27.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.179%.
Which hedge fund is a major shareholder of JMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7702
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JMS Co., Ltd.
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.